Thursday, April 20, 2017 5:00:45 PM
Marching orders are pipeline focus now
As we enter the final months of 2016, the key point to make for Sorrento is management efforts to provide significant
focus to its pipeline and drill down significantly from its broad assets and technologies. The goal is to have four to five
of Sorrento’s businesses moved significantly forward over the next 12 months. In order to accomplish this, the initial
focus should be on the following initiatives:
• Move a lead biosimilar program forward, likely in the hand of a partner. The company will focus on its lead
biosimilar for Erbitux and emphasize development in the U.S./E.U. Recall positive Phase III studies have
already been conducted in China, however these studies would not suffice for FDA filing. Once data start to
accumulate, the company will also assess whether this is potential for a “biobetter” path as well, which would
require more extensive studies and funding. We believe the biosimilar program represents the “low hanging
fruit” for the company while the earlier stage product candidates mature.
• Move forward with a lead CAR-T program from one of the top three programs (two solid, CEA and PSMA
and multiple myeloma). Based on the current struggles that CAR-Ts are having in solid tumors, we believe
the myeloma candidate may leapfrog the solid tumor candidates. Management is currently planning to
organically fund this lead program.
• Bring forward a lead ADC candidate from Concortis, which we believe will target c-Met. While the assets are
currently preclinical, Concortis is starting to provide meaningful CRO business to Sorrento and over time,
could potentially fund itself.
• Solidify path forward for Resiniferatoxin (RTX) for chronic pain associated with advanced cancer. The
product is part of the Scintilla subsidiary and on September 22, 2016, Scintilla announced the
commencement of an equity financing process. Part of the funds will be used to progress RTX to IND status
in early 2017 for cancer pain and begin Phase II studies in 2017.
Additionally, in order to further monetize the company’s assets, it will continue to, 1) Link with research collaborations,
2) Provide technology to others to validate candidates in specific geographies and 3) Enter partnerships for
candidates where appropriate.
Recent SRNE News
- Form 8-K - Current report • Edgar (US Regulatory) • 11/03/2023 09:31:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/27/2023 08:15:31 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM